Director/PDMR Dealings

RNS Number : 9170U
Arecor Therapeutics PLC
04 August 2022
 

4 August 2022

Arecor Therapeutics plc

("Arecor" or the "Company" or the "Group")

Director/PDMR Dealings

and

Completion of the Acquisition of Tetris Pharma

Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, announces t hat further to the Placing and acquisition of Tetris Pharma, details of which were announced on 1 August 2022, pursuant to the Placing, the following Directors subscribed for an aggregate amount of £113,271 at the Placing Price of 300 pence per ordinary share.

Following General Admission today, the Placing and acquisition of Tetris Pharma have now completed.

The following Directors interests in Ordinary Shares are as follows:

N ame

Placing Shares acquired

Resultant shareholding following Admission

% of the Enlarged Share Capital

Sarah Howell ( Chief Executive Officer)

6,666

847,072.00

2.8%

Susan Lowther ( Chief Financial Officer)

3,334

139,849.00

0.5%

Andrew Richards ( Chair)

6,666

223,834.00

0.7%

Sam Fazeli ( Non-Executive Director)

7,756

115,708.00

0.4%

J eremy Morgan ( Non-Executive Director)

6,666

27,169.00

0.1%

Christine Soden ( Non-Executive Director)

6,667

19,167.00

0.1%

Total

37,755



 

The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.00 a.m. on 1 August 2022 unless otherwise stated.

 

For more information, please contact:

 

Arecor Therapeutics plc

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com



Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com



Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: mo.noonan@arecor.com



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

 



Consilium Strategic Communications


Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

a)  Sarah Howell

b)  Susan Lowther

c)  Andrew Richards

d)  Sam Fazeli

e)  Jeremy Morgan

f)  Christine Soden

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

a)  Chief Executive Officer

b)  Chief Financial Officer

c)  Chair

d)  Non-executive Director

e)  Non-executive Director

f)  Non-executive Director

 

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Arecor Therapeutics plc

b)

 

LEI

 

 

98450093D12I3A8DDD58

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 1p each



Identification code

ISIN: GB00BMWLM973



b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




a)  300 pence

b)  300 pence

c)  300 pence

d)  300 pence

e)  300 pence

f)  300 pence

a)  6,666

b)  3,334

c)  6,666

d)  7,756

e)  6,666

f)  6,667







d)

 

Aggregated information




- Aggregated volume

37,755



- Price

300 pence



e)

 

Date of the transaction

 

 

4 August 2022

f)

 

Place of the transaction

 

 

XLON

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™ , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio

 

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBKQBPOBKKPFK
UK 100

Latest directors dealings